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http://dx.doi.org/10.1016/j.jmii.2013Background: Constructs composed of cell wall mannan-derived moieties conjugated to immu-
nogenic proteins could be promising agents for induction of protective anti-Candida immune
responses.
Methods: This report is focused on the cellular immune response differences induced by BSA-
based conjugates bearing synthetic a-1,6-branched oligomannosides. For monitoring of the im-
mune responses following active immunization we evaluated changes in the frequencies of T
and B lymphocytes and their activation status in the blood and spleen. We compared the
immunization-induced changes of co-stimulatory molecules CD80 and CD86 expression on
blood neutrophils and Th1/Th2 polarization of the immune response based on IFN-g, TNF-a
(pro-Th1), IL-4, and IL-10 (pro-Th2) cytokines levels and induction of IL-17.
Results: The results pointed out a comparable effect of the conjugates on the modulation of T
and B lymphocytes frequencies in blood and spleen. Both conjugates induced upregulation of
CD25 surface antigen on CD4þ T lymphocytes, independently on the structural differences of
oligosaccharides. The differences in structure of oligomannoside antigens or conjugate con-
structs were reflected in the increase of co-stimulatory molecules CD80 and CD86 expression
on neutrophils, and in induced cytokine response. M5eBSA conjugate induced only a slight in-
crease in CD80 expression but a significant increase in IFN-g, TNF-a, and IL-10. M6eBSA conju-
gate induced a significant increase of CD80 expression and increase of TNF-a, IL-4, and IL-10.Chemistry, Slovak Academy of Sciences, Du´bravska´ cesta 9, 84538 Bratislava, Slovakia.
(L. Paulovicova´).
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10 L. Paulovicova´ et al.Conclusion: Obtained data demonstrate the importance of cellular immune response analysis
for investigation of immunomodulatory properties of oligomannosideeprotein conjugates.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Candida albicans is a human commensal fungus that resides
on the skin, mucosa surfaces and gastrointestinal tract of
healthy individuals. This dimorphic organism can under
certain conditions invade mucosa through a phenotype
switch from yeast to hyphal form.1 Although C. albicans is
not pathogenic under normal host conditions, it can cause
infections when host defense is compromised. C. albicans is
associated with a wide spectrum of diseases in humans,
ranging from acute superficial infections of skin and
mucosal membranes due to impaired epithelial barrier
functions in immunocompetent individuals to inflammatory
diseases and severe life-threatening infections in immuno-
compromised patients.2 Systemic candidiasis is usually seen
in patients with cell-mediated immune deficiency, and
those receiving aggressive cancer treatment, immunosup-
pression, or transplantation therapy. There are several
predisposing factors for candidal infection, which include:
hostebarrier disruption (e.g. intravascular devices, severe
burns or recent surgery, intravenous catheters, invasive
procedures), prolonged hospitalization, malnutrition, use
of broad-spectrum antibacterial agents, bone marrow and
solid organ transplantation, chemotherapy or radiation
therapy, use of corticosteroids, hyperglycemia, primary or
secondary immunodeficiency syndromes (e.g. autosomal-
dominant hyper-IgE syndrome, severe combined immuno-
deficiency, CARD9 deficiency, IL-12p40 deficiency, DOCK8
deficiency, neutropenia, granulocytopenia, and AIDS).3,4
Acquired immunity to the fungus is usually present in
immunocompetent individuals, and is presumed to prevent
progression from colonization to symptomatic infection.1
Neutrophils predominantly contribute to the antifungal
innate immune response through phagocytosis and direct
candidacidal activity.2 Their absence is a major risk factor
for the susceptibility to Candida infections.5 Resistance to
disseminated C. albicans infection could be determined by
phagocytic mechanisms, the activity of which is amplified
by Th1 cytokines and impaired by Th2 cytokines. Thus, Th1,
and Th2 cells may be instrumental in activating the proper
anticandidal immune effector mechanism at the site of the
infection.6,7 The resistance is associated with the CD4þ Th1
immune responses.1,8 Moreover, Th1 cells provide help for
the production of opsonizing antibodies.2 Resistance to C.
albicans may be regulated by sets of opposing cytokines,
such as IFN-g and IL-4/IL-10.9
The outermost layer of the cell wall of Candida species
consists of mannoproteins containing O-glycosylated oligo-
saccharide and N-glycosylated polysaccharide moieties.
Both carbohydrate moieties have been shown to play an
essential role in host-fungal interactions, including the
triggering and modulation of the anti-Candida host immune
responses, which appear to rely on the interplay between
the innate and adaptive immunities.10 Endosomallyprocessed carbohydrates are presented by the MHC-II
pathway only when covalently conjugated to carrier pro-
teins and are presented by MHC-II only when linked to an
MHC-II binding peptide formed in the endolysosome by
proteolytic digestion of the carrier protein.11 Receptors
involved in signal induction by C. albicans mannan include
the mannose receptor, DC-SIGN, Galectin-3 and Dectin-2.2
Mentioned pattern recognition receptors could be
involved in receptor mediated internalization of mannosy-
lated protein antigens. Previously published studies of
mannosylated proteins or peptides antigenic presentation,
involving experiments with dendritic cells and mannosy-
lated BSA or mannosylated peptide antigens, revealed that
mannosylated antigens are presented more effectively than
non-mannosylated forms.12,13
Previous studies of mannan-derived glycoconjugates
immunomodulative properties were mainly focused on the
humoral immune response.14,15,16,17,18 Effect of C. dublin-
iensis mannan-HSA conjugate on T lymphocytes via induc-
tive increase of CD4þ T lymphocyte proportion, induction of
Th1 cytokines and increased expression of activation anti-
gen CD25 on B lymphocytes has been reported.19 Our
recently reported results of humoral and cell-mediated
immune response in response to synthetic heptamannosi-
deeBSA conjugate20 revealed relevance to supplement
the studies of humoral immune response induced by im-
munization with Candida mannan-derived moieties glyco-
conjugates with the analysis of cellular immune responses.
The objective of this study is to complement previously
published investigation of antibody response induced by
branched 3,6-di-O-substituted a-oligomannosides21 with
the investigation of cellular immunity modulation and to
compare obtained results with previously published
immunomodulative properties of heptamannosideeBSA
conjugate.20 Previously we showed that BSA-based conju-
gates bearing synthetic a-1,6-branched oligomannosides
(pentamannoside-M5eBSA and hexamannoside-M6eBSA)
mimicking antigenic sequences of Candida cell wall mannan
have structurally dependent potency to induce humoral
immune responses in mice, immunoglobulin isotype class
switch, and prepared anisera have different capacity to
improve candidacidal activity of polymorphonuclear leu-
kocytes.21 For monitoring of the cellular immune responses
to the two branched 3,6-di-O-substituted a-oligomanno-
sides (pentamannoside M5 and hexamannoside M6) conju-
gated to bovine serum albumin (BSA) we evaluated: (1) the
changes in the frequencies of T and B lymphocytes, (2)
activation status of CD4þ, CD8þ T cells in the blood and
spleen following active immunization, (3) immunization-
induced changes of co-stimulatory molecules CD80 and
CD86 expression on blood neutrophils, and (4) Th1/Th2
polarization of the immune response based on IFN-g, TNF-a
(pro-Th1), and IL-4, IL-10 (pro-Th2) cytokines levels and
induction of IL-17.
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Characterization of oligosaccharide-BSA conjugates
We investigated immunomodulatory properties of two syn-
thetically prepared manno-oligosacharides contained a-
1,6-linked branched mannose units in addition to a-1,2-, a-
1,3-linked mannose residues (a-pentamannoside M5 and a-
hexamannoside M6) conjugated to BSA (Fig. 1). Oligo-
mannosides M5 and M6 represent structures of antigenic
determinants related to Candida antigenic factor 4 and
were detected in the C. albicans acid-stabile mannan
part.22,23 Conjugation of BSA with synthetic spaced oligo-
mannoside derivatives M5 and M6 was performed by the
squarate method.24 According to MALDI TOF mass spec-
trometry analysis the M5eBSA conjugate contained on
average 10 pentamannoside and conjugate M6eBSA con-
tained on average nine hexamannoside residues per one
BSA molecule.24
Immunization
Mice (40 animals per one conjugate, female, 6 weeks old,
BALB/c, Research Institute of Animal Production Velaz,
Prague, Czech Republic) were used for immunization. Pri-
mary dose of conjugate was administered subcutaneously
(1st dose) without adjuvant (6 mg oligosaccharide in 100 ml
per mouse per 1 dose) and mice were subsequently sub-
cutaneously boosted (2nd dose, primary boost) without
adjuvant 2 weeks after primary injection. Two weeks after
primary booster injection mice were divided into two
groups and were secondary boosted by subcutaneous (3rd sc
dose) or intraperitoneal (3rd ip dose) administration of the
same conjugate amount without adjuvant. The mice in
control group (10 animals) were injected three times sub-
cutaneously with saline, following the same time schedule.
Blood and spleens were collected at Day 14 following each
injection. Animal experiments were conducted in accor-
dance with the criteria for the welfare of experimental
animals, and complied with the ethical guidelines issued by
the Research Base of Slovak Medical University, Institute of
Preventive and Clinical Medicine (Bratislava, Slovakia)
under the approval No. Ro 2939/09-221 of the State Vet-
erinary and Food Administration of the Slovak Republic.Figure 1. Structures of BSA-based glycMice were housed under standard laboratory conditions,
fed a standard pelleted diet and had access to tap water ad
libitum.
Lymphocyte surface markers staining and flow
cytometric analysis
Blood samples (n Z 10 mice from each group) were
collected into EDTA tubes and placed on ice. Spleens
(n Z 10 mice from each group) aseptically removed from
immunized and control mice were placed in ice cold PBS.
Splenocytes were obtained by repeated flushing of spleen
with sterile PBS (1 mL per spleen). For immunofluorescence
staining 50 mL aliquots of the samples (blood, splenocytes)
were incubated with monoclonal antibodies for 30 minutes
at 4C in the dark. For analysis, cells were stained with
appropriate combinations of monoclonal antibodies: Anti-
Mouse CD3-FITC (clone KT3, Rat IgG2a), Anti-Mouse CD4-
FITC (clone YTS, Rat IgG2b), Anti-Mouse CD4-PE (clone
YTS, Rat IgG2b), Anti-Mouse CD8a-FITC (clone KT15, Rat
IgG2a, l), Anti-Mouse CD8a-PE (clone KT15, Rat IgG2a, l),
Anti-Mouse CD19-FITC (clone 6D5, Rat IgG2a), Anti-Mouse
CD25-PE (clone Y6, Mouse IgM), Anti-Mouse CD80-PE
(clone YTS, Rat IgG2b), Anti-Mouse CD86-PE (clone YTS,
Rat IgG2b), Anti-Mouse CD38-PE (clone YTS, Rat IgG2b),
Anti-Mouse CD28-PE (clone YTS, Rat IgG2b), Anti-Rat IgG2a-
FITC (clone YTS, Rat IgG2b), Anti-Rat IgG2b-PE (clone YTS,
Rat IgG2b), Anti-Mouse IgM-FITC (clone YTS, Rat IgG2b)
(Antigenix America Inc., USA). Lysis of erythrocytes was
performed by incubation (30 minutes at 4C) with 250 mL of
Optilyse C lysing solution (Immunotech, A Beckman Coulter
Company, USA). Samples were analyzed with a FC 500 flow
cytometer (Beckman Coulter Inc., Fullerton, CA, USA) in
triplicate. Lymphocytes and neutrophils were gated ac-
cording size and granularity.
Detection of cytokines in sera
Cytokine concentrations in sera (n Z 10 mice from each
group) were analyzed by Mouse TNF-a Instant ELISA kit,
Mouse IL-4 Instant ELISA kit, Mouse IFN-g Instant ELISA kit
Mouse IL-10 Instant ELISA kit and Mouse IL-17A Platinum
ELISA kit (Bender MedSystems, Vienna, Austria) according
to the manufacturer’s protocol. Samples were analyzedoconjugates M5eBSA and M6eBSA.24
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measurements at 450 nm and 620 nm. Cytokine concen-
trations were determined by a standard curve and
expressed in pg/mL.
Statistical analysis
Data were evaluated for statistical significance of differ-
ences by one-way ANOVA followed by Bonferroni’s multiple
comparison tests and Spearman’s rank correlation test.
All data were expressed as mean  SD. Levels of statistical
significance of differences: *** p < 0.001, ** 0.001 <
p < 0.01, * 0.01 < p < 0.05.
Results
Effect of immunization on B and T lymphocytes
frequencies in blood and spleen
To determine the effects of M5eBSA and M6eBSA glyco-
conjugate immunizations on cell-mediated adaptive im-
munity we analyzed the proportion of CD3þ and CD19þ
lymphocytes in blood and spleen of immunized mice and
compared them with control animals. We observed slight
differences in kinetics of blood CD3þ T lymphocytes pro-
portion changes induced by M5eBSA and M6eBSA conju-
gates (Fig. 2). The M6eBSA conjugate induced an increase
of mean CD3þ T lymphocytes in blood after the primary sc
injection (1.13 times), which turned into a decreasingFigure 2. Changes of CD3þ and CD19þ lymphocytes population p
CD19þ cells within lymphocyte populations in blood and spleen.
Presented results are 14 days after the primary sc injection (1st), t
(3rd ip) and the secondary sc booster (3rd sc) injection of M5eBSA
mean  SD and statistical significance of differences between im
*0.01 < p < 0.05.tendency after the primary sc booster injection. After the
secondary booster injection of M6eBSA conjugate CD3þ T
lymphocytes percentage decreased to values lower than
(secondary ip booster) or comparable with (secondary sc
booster) controls (Fig. 2). Contrary to M6eBSA conjugate,
M5eBSA conjugate induced slight increase of CD3þ T lym-
phocytes proportion only after the secondary sc booster
injection. Observed kinetics of CD3þ T lymphocytes pro-
portion changes indicated more intensive effect of M6eBSA
conjugate immunization on CD3þ T lymphocytes after the
first dose, although without persistence. The changes of
CD3þ T lymphocytes proportion in spleen induced by im-
munization with M5eBSA and M6eBSA conjugates showed
moderate cross-correlation (r Z 0.85, p Z 0.15) and indi-
cated similar impact on CD3þ T lymphocytes. However,
after secondary sc booster injection of M5eBSA conjugate
more marked decrease of CD3þ T lymphocytes proportion in
comparison with secondary sc booster injection of M6eBSA
conjugate was detected (Fig. 2). Both conjugates induced
the increase of CD19þ B lymphocytes proportion in blood
with significant peak after primary sc booster injection
(Fig. 2). Detected increase was slightly higher with M5eBSA
conjugate (2.77 times higher than control) compared to
M6eBSA conjugate (2.38 times higher than control) and
obtained results reveal correlation of CD19þ B lymphocytes
proportion changes induced by M5eBSA and M6eBSA con-
jugates (r Z 0.98, p Z 0.02). Changes of CD19þ B lym-
phocytes proportion in spleen induced by immunization
with M5eBSA and M6eBSA conjugates differ only after
primary sc injection. In contrast to M6eBSA conjugate,ercentage in blood and spleen. Mean percentage of CD3þ and
Control represents mice after the 3rd sc injection of saline.
he primary sc booster injection (2nd), the secondary ip booster
conjugate or M6eBSA conjugate. All data were expressed as
munized mice and controls: ***p < 0.001, **0.001 < p < 0.01,
Immune response to branched a-oligomannoside conjugates 13M5eBSA conjugate induced increase of CD19þ B lympho-
cytes proportion in spleen after primary sc injection (1.15
times higher than control, Fig. 2). The decrease of CD19þ B
cells in blood and spleen could be related to the maturation
of B lymphocytes as indicated by significant increase of
CD19eCD38þ plasma cells in spleen (Table 1).
Immunization effect on CD3DCD4D and CD3DCD8D
T lymphocytes proportion in blood and spleen
M5eBSA and M6eBSA conjugates immunization induced a
slight decrease or no alteration in the proportion of
CD3þCD4þ T lymphocytes in blood (Table 2) in comparison
with controls. M5eBSA conjugate induced a slight increase
of CD3þCD8þ T lymphocytes in blood after the primary sc
booster and secondary ip booster injection. M6eBSA con-
jugate induced a slight increase of CD3þCD8þ T lympho-
cytes in blood only after the secondary ip booster injection.
In spleen, both conjugates induced an initial increase of
mean CD3þCD4þ T lymphocytes after primary injection,
followed by decrease to values comparable with controls
(Table 2). In addition, the kinetics of CD3þCD8þ T lym-
phocytes proportion changes in spleen showed similar
trends for both conjugates (Table 2). The mean percentage
of CD3þCD8þ T lymphocytes decreased after primary in-
jection and afterwards increased to values comparable
with controls or slightly higher (M5eBSA conjugate sec-
ondary sc booster). The preferred immune response
inducing an increase of CD3þCD4þ T lymphocytes contrary
to CD3þCD8þ T lymphocytes was induced by primary
administration of conjugates, as is evident from the
CD3þCD4þ/CD3þCD8þ cell ratio in spleen (control: 2.5,
primary administration of M5eBSA: 3.2, primary adminis-
tration of M6eBSA: 3.8).
Activation of CD4D and CD8D T lymphocytes in
blood and spleen
In order to assess the activation state of CD3þCD4þ and
CD3þCD8þ T lymphocytes in blood and spleen of immunized
mice, the expression of the lymphocyte activation marker
CD25 was analyzed (Fig. 3). We observed a higher mean




1st d 21.3  0.4 26.1  0.2
2nd d 35.6  0.4 30.2  0.3
3rd ip d 42.1  0.5 41.3  0.2
3rd sc 27.0  0.5 42.6  0.3 47.4  0.5
CD19eCD38þ lymphocytes population percentage in spleen
after the primary sc injection (1st), the primary sc booster in-
jection (2nd), the secondary ip booster (3rd ip) and the sec-
ondary sc booster (3rd sc) injection of M5eBSA conjugate or
M6eBSA conjugate. Control represents mice after the 3rd sc
injection of saline. All data are expressed as mean  SD.proportion of CD8þCD25þ cells in blood during immuniza-
tion with both oligomannosideeBSA conjugates compared
with the controls. M5eBSA conjugate induced the highest
percentage of CD4þCD25þ cells in blood after primary sc
booster injection and M6eBSA conjugate induced the
maximal peak of CD4þCD25þ cells proportion after primary
sc administration. In spleen, the immunization with both
conjugates induced a significant increase of CD4þCD25þ
cells mean proportion after primary sc injection with sub-
sequent decreasing tendency (Fig. 3). The percentage of
CD4þCD25þ cells in the spleen after each administration
remained higher in comparison with controls for both con-
jugates and both administration routes of secondary
booster injection. M5eBSA conjugate immunization
induced statistically significant increase in the percentage
of CD8þCD25þ cells in the spleen with the maximal peak
after the primary sc injection (Fig. 3). M6eBSA conjugate
induced a marked significant increase in the proportion of
CD8þCD25þ cells only after primary sc administration
(Fig. 3). The results obtained indicate the highest rate of
CD4þ T lymphocyte activation after primary injection with
both conjugates. Activation of CD4þ T lymphocytes appears
to be only slightly dependent on the structural differences
of conjugates. In parallel with an increase in the proportion
of CD4þCD25þ cells we did not observe a directly depen-
dent increase in the IL-10 concentration in sera of immu-
nized mice. Although the IL-10 levels did not correlate with
the induction of CD4þCD25þ cells, we assume inductive
activation of the CD4þ T cell subset rather than regulatory T
cells generation.Upregulation of co-stimulatory antigens CD80 and
CD86 expression on neutrophils
We analyzed the expression of activation and co-
stimulatory antigens CD80 and CD86 on neutrophils
(Fig. 4). Expression of CD80 and CD86 antigens revealed a
different characteristic of M5eBSA and M6eBSA conju-
gates. Both conjugates induced an increase of CD80
expression after the primary sc administration (Table 3),
with a subsequent decrease after the primary booster in-
jection. Secondary sc and secondary ip booster injection of
M6eBSA conjugate induced a significant increase of CD80
expression on neutrophils. The secondary booster injection
of M5eBSA conjugate (both administration routes) did not
induce significant changes of CD80 expression on the neu-
trophils. For the expression of CD86 co-stimulatory antigen
on neutrophils, we observed the highest induction after
primary sc injection, with subsequent decrease after pri-
mary sc booster and secondary booster (sc, ip) injections
(Table 3). A decrease of CD86 expression on neutrophils was
more significant for M5eBSA, compared to M6eBSA conju-
gate (Table 3). The CD28 receptor expressed on T cells
serve as a surface component of the signal transduction
pathway, which can provide co-stimulation. Interaction of
CD28 with CD80 and CD86 expressed on the surface of an-
tigen presenting cells can induce proliferation and cytokine
production in T cells activated via an antigen receptor. In
parallel with alterations of CD80 and CD86 expression on
neutrophils, we observed no dynamics of the expression of
CD28 antigen on T lymphocytes (data not shown).
Table 2 Immunization-related changes in percentage values of CD3þCD4þ and CD3þCD8þ T lymphocyte subsets in blood and
spleen
Injection Blood Spleen
CD3þCD4þ CD3þCD8þ CD3þCD4þ CD3þCD8þ
M5eBSA M6eBSA M5eBSA M6eBSA M5eBSA M6eBSA M5eBSA M6eBSA
1st 77.2  0.4 78.9  2.0 22.9  1.1 20.7  1.2 74.4  0.8 76.4  0.1 22.9  1.8 20.1  3.4
2nd 76.1  0.6 79.9  1.6 24.2  0.4 20.1  2.1 71.4  1.4 68.9  0.2 26.0  0.1 27.1  0.3
3rd ip 77.0  1.5 73.1  1.5 24.3  1.2 23.4  1.2 70.7  1.4 70.7  1.4 26.8  1.3 26.1  1.3
3rd sc 76.8  1.5 75.9  1.5 20.6  1.0 20.5  1.0 66.7  1.3 71.2  1.4 30.5  1.5 26.2  1.3
Control 79.1  1.6 21.8  1.1 69.1  1.4 27.5  1.4
Mean percentage values of CD3þCD4þ and CD3þCD8þ lymphocytes within CD3þ T lymphocyte populations in blood and spleen. Presented
results are 14 days after the primary sc injection (1st), the primary sc booster injection (2nd), the secondary ip booster (3rd ip) and the
secondary sc booster (3rd sc) injection of M5eBSA conjugate or M6eBSA conjugate. Control represents mice after the 3rd sc injection of
saline. All data are expressed as mean  SD.
14 L. Paulovicova´ et al.Analysis of immunization-induced changes in
cytokine levels
Considering that cytokines regulate the type and extent of
generated immune response, we analyzed IFN-g, TNF-a,
IL-4, IL-10, and IL17 concentrations in the sera of control
mice and immunized mice after each conjugate adminis-
tration (Fig. 5). Significant differences were observed in the
induction of cytokines between M5eBSA and M6eBSAFigure 3. Immunization-related changes in percentage values o
centage of CD25þ cells within CD4þ T lymphocytes and within CD8
after the 3rd sc injection of saline. Presented results are 14 days
jection (2nd), the secondary ip booster (3rd ip) and the secondary s
All data were expressed as mean  SD and statistical significa
*** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05.conjugates. M5eBSA conjugate immunization induced
significantly higher levels of IFN-g after primary sc booster
injection (3.9 times) and secondary ip booster injection
(10.4 times) in comparison with control and significant in-
crease of TNF-a after secondary booster injection (ip:
2.3 times, sc: 1.8 times). Secondary ip booster injections of
M5eBSA conjugate induced also significant increase of IL-
10 (4.1 times in comparison with control) but less pro-
nounced than the increase of IFN-g. M5eBSA conjugatef CD4þCD25þ and CD8þCD25þ T cells in blood and spleen. Per-
þ T lymphocytes in blood and spleen. Control represents mice
after the primary sc injection (1st), the primary sc booster in-
c booster (3rd sc) injection of M5eBSA and M6eBSA conjugates.
nce of differences between immunized mice and controls:
Figure 4. Flow cytometry analysis of CD80 and CD86 expression. The diagrams show single-parameter histograms, the gray area
represents control mice after the 3rd sc injection of saline and the black line represents immunized mice after the secondary ip
booster (3rd ip) and the secondary sc booster (3rd sc) administration of M5eBSA conjugate and M6eBSA conjugate.
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secondary ip booster injection (1.7 times higher than con-
trol). Contrary to the M5eBSA conjugate, M6eBSA conju-
gate did not increase the levels of IFN-g and induced a
statistically significant increase of TNF-a with maximal
value after primary sc booster injection (1.8 times higher
than control). Moreover, M6eBSA conjugate induced a
marked increase of IL-4 (5.9 times higher than control) and
IL-10 (10.2 times higher than control) after primary sc
booster injection. Both conjugates did not affect the levels
of IL-17 (Fig. 5). Upon alterations of IFN-g, TNF-a, and IL-4
sera levels we can suppose induction of Th1 immune
response over Th2 by M5eBSA conjugate immunization and
Th2 immune response over Th1 induced by M6eBSA conju-
gate immunization.Table 3 Expression of CD80 and CD86 on neutrophils
Injection MFIa
CD80 CD86
Control 3rd sc 9.6  0.2 11.5  0.3
M5eBSA 1st 19.2  0.7*** 15.5  0.4**
2nd 11.8  0.2 10.1  0.4
3rd ip 13.9  0.6* 11.6  0.5
3rd sc 13.1  0.4* 10.9  0.3
M6eBSA 1st 20.5  0.3*** 19.4  0.3***
2nd 15.5  0.4** 14.1  0.5*
3rd ip 20.3  0.2*** 13.7  0.3**
3rd sc 24.1  0.4*** 14.4  0.2**
a The values are means of the fluorescence intensities (MFI).
CD80 and CD86 expression on neutrophils analyzed 14 days after
the primary sc injection (1st), the primary sc booster injection
(2nd), the secondary ip booster (3rd ip) and the secondary sc
booster (3rd sc) injection of M5eBSA conjugate and M6eBSA
conjugate. All data were expressed as mean  SD and statistical
significance of differences between immunized mice and con-
trols: *** p < 0.001, ** 0.001 < p < 0.01, *0.01 < p < 0.05.Discussion
A mannan forms the outermost layer of the Candida species
cell wall and has an important role in modulation of the
anti-Candida host immune responses and hostefungal in-
teractions [10]. Previously published studies indicate
ability of antibodies against b-1,2-linked mannotriose or
mannobiose to protect mice against hematogenously
disseminated candidiasis.14,15,16,25 Antibodies induced by
immunization with synthetic a-dimannoside-BSA conjugate
and heptamannoside-BSA conjugate also showed poten-
tially protective character.20,26 Previously published results
of branched 3,6-di-O-substituted oligomannoside-BSA con-
jugates reveal structure dependent immunogenicity and
limited capacity of branched a-manno-oligosides conju-
gates to induce production of potentially protective anti-
bodies21 in comparison with linear manno-oligomers,20,26
especially influenced by branching difference at non-
reducing end of the oligomers.
T cell activation is an important point in the develop-
ment of optimal and protective anti e Candida immunity.5
The Th1 cell-mediated immune response is considered
to be a protective host defense mechanism against
mucosal27,28 and systemic29 Candida infections. Glyco-
conjugates using manno-oligomers as the main protective
antigen coupled to a protein or peptide carrier have the
capacity to be immunogenic and protective against exper-
imental candidiasis.14,16e18 Studies on the immunobio-
logical properties of mannan-derived glycoconjugates have
been mainly focused on the humoral immune response and
production of protective antibodies. We extended the
oligomannoside-BSA conjugate immunomodulatotion study
by analysis of cellular immune responses. BSA based gly-
coconjugate of linear heptamannoside ligands containing a
terminal b-1,2-linked mannose unit in addition to a-1,2-, a-
1,3-linked mannose units induced initial increase of
CD45þCD19þ B lymphocytes proportion with subsequent
increase of mannan specific antibody levels and differen-
tiation of B lymphocytes into plasma cells.20 They also
Figure 5. The immunization-related changes in cytokines
concentrations. Kinetics of IFN-g, TNF-a, IL-4, IL-10, and IL-17
concentration changes in sera induced by the primary sc in-
jection (1st), the primary sc booster (2nd), the secondary ip (3rd
ip) and the secondary sc (3rd sc) booster injection of M5eBSA
conjugate and M6eBSA conjugate. Control represents mice
after the 3rd sc injection of saline. All data were expressed
as mean  SD and statistical significance of differences
between immunized mice and controls: *** p < 0.001,
** 0.001 < p < 0.01, * 0.01 < p < 0.05.
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blood, activation of CD4þ T lymphocyte, balanced Th1/Th2
immune response polarization, significant increase of IL-17,
and only slight or no increase of IL-10, representing very
low induction of regulatory T cells and immunosuppressive
response. In this study, we followed alterations of cellular
immunity in response to immunization with Candida
mannan-derived branched 3,6-di-O-substituted a-oligo-
mannosides conjugated to BSA (M5eBSA and M6eBSA con-
jugates). The changes of the proportion of the blood and
spleen immunocytes, activation status of T lymphocytes
and neutrophils, and T cells polarization-associated cyto-
kines in response to M5eBSA and M6eBSA conjugate im-
munizations were analyzed. Specific antibodies could have
an important role for protection against Candida infection,5
therefore understanding of B cell dynamics following im-
munization is of great relevance. Both conjugates induced
comparable increases of mean proportions of CD19þ B
lymphocytes in blood after the primary sc and the primary
sc booster injection. A subsequent decrease in the pro-
portion of CD19þ B lymphocytes after secondary booster
injection may be indicative of regression of the CD19þ
marker and B cells differentiation into antibodies secreting
plasma cells. Simultaneously, with a decrease in the pro-
portion of CD19þ B lymphocytes, we observed a significant
increase in CD19eCD38þ plasma cells percentage in spleen.
The results obtained were also confirmed by previously
published increases of mannan-specific antibodies produc-
ing cells counts during M5eBSA and M6eBSA immuniza-
tion.21 Moreover, published results regarding the humoral
immune response revealed an IgM to IgG isotypes class
switch induced by M6eBSA conjugate and slightly improved
candidacidal activity of polymorphonuclear leukocytes
induced by opsonization with M6eBSA conjugate antisera.21
Analysis of the proportion of B lymphocytes in the blood and
spleen after each dose of conjugates completed the infor-
mation about the mechanisms underlying generation of
specific antibodies and pointed out the similarity with
previously published results of the impact of heptamanno-
sideeBSA conjugate immunization on CD19þ B lympho-
cytes.20 Both conjugates induced similar kinetics of mean
CD3þ T lymphocytes proportion changes in spleen, with
marked increase after the primary sc booster injection
(M5eBSA: 1.25 times higher, M6eBSA: 1.19 times higher in
comparison with control). Contrary to the M5eBSA conju-
gate, the M6eBSA conjugate also induced an initial increase
of mean CD3þ T lymphocytes proportion in blood (primary
injection: 1.13 times higher than control) with subsequent
decreasing tendency. For both conjugates, immunization
did not significantly affect the CD3þCD4þ and CD3þCD8þ T
lymphocytes proportions in blood or in spleen. The results
obtained indicate a lower impact of branched a-oligo-
mannosideeBSA conjugates on CD3þ T lymphocytes and
CD3þCD4þ T lymphocytes proportions in comparison with
previously published results exploring the immunomodula-
tory properties of mannan-derived linear heptamannosi-
deeBSA conjugate that induced significant increase of
CD3þCD4þ T lymphocytes proportions and decrease of
CD3þCD8þ T lymphocytes proportions in blood.20 The effect
of immunization on T lymphocyte activation has been
investigated by measuring the activation marker CD25 on
CD3þCD4þ and CD3þCD8þ lymphocytes. Both conjugates
Immune response to branched a-oligomannoside conjugates 17induced significant increase of CD25 expression on blood
and spleen CD4þ T lymphocytes. Markedly higher activation
of CD4þ T lymphocytes has been detected in spleen, with
maximal intensity after the primary sc injection. Previously
published induction of CD25 expression on blood CD4þ T
lymphocytes observed throughout the immunization with
linear heptamannosideeBSA conjugate, together with the
results obtained with branched 3,6-di-O-substituted a-oli-
gomannosideeBSA conjugates M5eBSA and M6eBSA, sug-
gested the activation of CD4þ T lymphocytes, as a common
structure-independent feature related to synthetic oligo-
mannosideeBSA conjugates. The population of CD4þ T cells
expressing CD25 could represent regulatory T cells (Treg),
although CD25 expression did not fully characterize Treg.
However, CD4þCD25þ Treg cells are related to IL-10 pro-
duction and are not generated in the absence of IL-10.30,31
We did not observe a cross-correlation of IL-10 levels and
CD25 expression on CD4þ T lymphocytes during immuniza-
tion. Based on the results obtained, we assumed
CD4þCD25þ T lymphocytes to be activated cells, instead of
CD4þCD25þ Treg cells.
Neutrophils have an ability to directly activate T cells in
an antigen- and MHC-II-dependent manner32 and are able to
initiate T cell differentiation to Th1 and Th17 effector
subsets.33 Upon stimulation, neutrophils can be induced to
express MHC-II and co-stimulatory molecules CD80 and
CD86, and are able to trans-differentiate into dendritic-like
cells.33 Peripheral murine or human polymorphonuclear
neutrophils (PMN) are able to discriminate between yeast
and the hyphal form of the fungus. The exposure to Candida
hyphae induces increased expression of CD80 on the surface
of neutrophils (unlike cells in yeast form). IL-4, more than
IL-10, appears to be involved in the regulation of CD80
expression on PMN after exposure to Candida.34 Murine
neutrophils, expressing the CD80 upon exposure to hyphae
could adversely affect the development of antifungal Th1
immunity.34 Throughout the immunization with branched
3,6-di-O-substituted a-oligomannosideeBSA conjugates we
observed initially marked increase of CD80 and CD86
expression on blood neutrophils after the primary admin-
istration for both conjugates with subsequent decrease
after primary sc booster injection. Secondary booster in-
jections of M5eBSA conjugate (both administration routs)
did not induce significant increase of CD80 and CD86
expression on neutrophils. Contrary to M5eBSA conjugate,
the secondary sc and the secondary ip booster injections of
M6eBSA conjugate markedly enhanced expression of CD80.
Expression of the CD86 co-stimulatory molecule on neu-
trophils also slightly increased for M6eBSA conjugate. The
primary increase of CD86 expression on neutrophils could
be related to early expression that is important in initiating
an immune response,35 while later expressed CD80 could
amplify or regulate the immune response.36 Neutrophils
expressing CD80 are able to negatively affect Th1-
dependent resistance in fungal infections, through inhibi-
tion of interferon IFN-g producing CD4þ T cells via CD80/
CD28-dependent mechanisms.34 The immunization with
M6eBSA conjugate did not induce a CD80 increase related
increase of CD28 expression on CD4þ T cells (data not
shown).
We analyzed the induction of Th2-related cytokines IL-4
and IL-10, Th1-associated cytokines IFN-g and TNF-a, andTh17-related cytokine IL-17. M6eBSA conjugate induced a
significant increase of IL-4 and IL-10 concentrations,
markedly higher in comparison with M5eBSA conjugate,
indicating the induction of a Th2 over a Th1 immune
response. In contrast to M6eBSA conjugate, M5eBSA con-
jugate immunization induced a marked increase of IFN-g
and TNF-a concentrations, especially after the primary sc
booster injection, which could be indicative for effective
activation of professional phagocytes and possible anti-
fungal activity. Moreover, the Th2 response and IL-4 release
mainly correlates with candidiasis progression and pathol-
ogy.29 M5eBSA conjugate immunization induced in addition
to IFN-g and TNF-a also increase of IL-10 with potent anti-
inflammatory properties, repressing the expression of in-
flammatory cytokines such as TNF-a. When we compared
the levels of cytokines with expression of co-stimulatory
molecules, we observed a significant relationship between
increase of CD80 expression on neutrophils and increase of
IL-4 and IL-10 concentrations induced by M6eBSA conjugate
immunization. It was described that IL-4 can be involved in
the regulation of CD80 expression on polymorphonuclear
neutrophils after exposure to Candida.34
The immune-promoting activity of immunization is
determined by the presence of the relevant antigenic
components in the vaccine formulation, enhanced by the
addition of suitable adjuvants capable of activating and
promoting an efficient immune response against infectious
agents. Various adjuvants have a different effect the im-
mune response induced. The incorporation of pathogens
associated molecular patterns (PAMPs) in vaccine formula-
tions can improve and accelerate the induction of specific
responses.37 Our approach was to study the immunomodu-
latory effect of oligomannosideeBSA conjugates on cellular
immunity without the contribution of adjuvants. Efficient
control of Candida infection relies on the generation of a
protective Th1 response.38 The importance and effect of
IFN-g was confirmed by reduction of the C. albicans
outgrowth in organs of mice with disseminated candidi-
asis.39 The immunized mice cytokine profile analysis indi-
cate upregulation of the Th2 cell-mediated immune
response induced by immunization with M5eBSA conjugate
and upregulation of the Th1 cell-mediated immune
response induced by M6eBSA conjugate immunization.
Current opinion is that Th1 responses characterize the
carriage of saprophytic yeast and the resistance to disease
seen in healthy humans, whereas Th2 responses are asso-
ciated predominantly with pathology observed in immuno-
compromised hosts.40 Based on the results obtained, we
can suppose that used branched oligomannosideeBSA con-
jugates vary in their ability to induce an effective and
protective immune response against Candida infection. One
of the differences involves neutrophils expression of co-
stimulatory molecules CD86 and CD80 and Th1/Th2 polari-
zation of immune responses. The present study on synthetic
glycoconjugates immunomodulatory properties is a part of
continuous effort to find the suitable antigenic structure for
an effective anti-Candida immune response. Previously
reported results on humoral immunity modulation,21 as well
as results presented here on the cellular immune response
reveal that even the small structural changes in manno-
oligosaccharide antigen or conjugate construct could
evoke observable differences in hosteimmune responses.
18 L. Paulovicova´ et al.Which parameters are the most important, and therefore
should be monitored, is still an open question and requires
further investigation.
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